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Abstract 
Mutolide an anti‑inflammatory compound was isolated from the coprophilous fungus Lepidosphaeria sp. 
(PM0651419). The compound mitigated LPS‑induced secretion of pro‑inflammatory cytokines TNF‑α and IL‑6 from 
THP‑1 cells as well as human peripheral blood mononuclear cells (hPBMCs). Mutolide also inhibited secretion of 
another pro‑inflammatory cytokine IL‑17 from anti‑hCD3/anti‑hCD28 stimulated hPBMCs. NF‑κB is the major tran‑
scription factor involved in the secretion of pro‑inflammatory cytokines including IL‑17. Mechanistic evaluations 
revealed that mutolide inhibited induced NF‑κB activation and translocation from cytoplasm into the nucleus. How‑
ever, mutolide did not significantly affect activity of p38 MAPK enzyme, a serine/threonine kinase involved in cell cycle 
proliferation and cytokine secretion. These results indicate that mutolide may exert its anti‑inflammatory effect via 
NF‑κB inhibition. Oral administration of mutolide at 100 mg/kg showed significant inhibition of LPS‑induced release of 
TNF‑α from Balb/c mice in an acute model of inflammation. Our results highlight the anti‑inflammatory properties of 
mutolide and suggest that further evaluation in a chronic model of inflammation is required to confirm the potential 
of mutolide as a druggable candidate for the treatment of inflammatory diseases.
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Background
Inflammation is a complex response to harmful stim-
uli like microbial infection, endotoxin exposure, dam-
aged cells or irritants. Lipopolysaccharide (LPS), which 
is produced by Gram negative bacteria, binds to CD14/
TLR4/MD2 receptor complex, especially in monocytes, 
dendritic cells, macrophages and B cells. This results in 
activation of a complex biochemical cascade that pro-
motes the recruitment of MyD88, activation of protein 
kinases, recruitment of the adaptor protein TRAF6, and 
subsequent activation and translocation of NF-κB and 
AP-1 into the nucleus. NF-κB activation is mediated by 
phosphorylation of IκB after LPS stimulation culminating 
in dissociation of the IκB complex leading to transloca-
tion of NF-κB into the nucleus wherein it interacts with 
promoter regions of various genes encoding pro-inflam-
matory mediators. The activation of NF-κB results in 
excessive production of pro-inflammatory cytokines such 
as TNF-α, IL-6, and IL-1β. Several studies have impli-
cated the role of TNF-α, IL-1β, IL-6 in the pathogenesis 
of a number of inflammatory diseases, such as inflam-
matory bowel disease (IBD), rheumatoid arthritis, sepsis 
and mucositis. Since the discovery of TNF-α antibody 
for the treatment of RA (Feldmann et al. 1996) biologists 
are targeting TNF-α to reduce inflammatory reactions in 
the body and restore the cytokine balance. Tociluzumab, 
a humanized anti-IL-6 receptor antibody has achieved a 
very good ACR70 response in human clinical trials for 
RA (Smolen and Maini 2006). Thus, anti-IL-6 treatment 
is also considered an important strategy for therapeutic 
intervention. Recent developments with the anti-IL-17 
and anti-IL-23 strategies have shown clinical success in 
the treatment of psoriasis (Griffiths et al. 2010; Leonardi 
et al. 2012; Papp et al. 2012). The clinical success of these 
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anti-cytokine strategies has increased the focus of phar-
maceutical drug discovery on identifying small molecule 
inhibitors of cytokines such as TNF-α, IL-6, IL-17 and 
IL-23 (Kulkarni-Almeida et al. 2008).
Historically, the best resources for novel scaffolds have 
always been natural products. A number of studies have 
reported that natural products show anti-inflammatory 
activity by controlling the levels of various inflammatory 
cytokines or inflammatory mediators including TNF-α, 
IL-6, IL-1β, NF-κB, JAK, STAT, NO, iNOS, COX-1 and 
COX-2 (Debnath et  al. 2013; Gautam and Jachak 2009). 
Amongst natural products, fungi are a rich source of 
chemical diversity (Deshmukh and Verekar 2012; Guna-
tilaka 2006; Kharwar et  al. 2011; Newman and Cragg 
2007), and its metabolites are used by the pharmaceuti-
cal industry in either the native form or as derivatives 
(Aly et al. 2011; Bernier et al. 2004). As only a small part 
of the mycota is known and most fungi produce several 
unknown metabolites, fungi are still one of the most prom-
ising sources for new lead compounds. Fungal metabolites 
are known potential anti-inflammatory agents and act on 
targets such as iNOS, NF-κB, AP-1, JAK, STAT, cytokines, 
cyclooxygenase (COX-1 and COX-2), 3β-HSD, XO and 
PLA2: Rutilins A and B isolated from Hypoxylon rutilum, 
an inhibitor of NO production(Quang et  al. 2006), Glio-
virin isolated from Trichoderma harzianum, an inhibitor 
of inducible TNF-α expression (Rether et al. 2007), Pane-
poxydone isolated from Lentinus crinitus, an inhibitor of 
NF-κB activation (Erkel et al. 1996), Phomol isolated from 
Phomopsis sp. inhibitor of edema in the mouse ear assay 
(Weber et al. 2004), Ergoflavin isolated from an endophytic 
fungus of Mimosops elengi, an inhibitor of human TNF-α 
and IL-6 (Deshmukh et al. 2009), are but a few examples.
In our ongoing pharmacological screening program 
on biodiversity of fungi present in Indian landscape 
using high throughput screening (HTS); we discovered a 
remarkable anti-inflammatory activity in extracts/frac-
tions of a fungus Ascomycota, coded as PM0651419. The 
14-membered macrolide, mutolide, was isolated by bioac-
tivity guided isolation. This macrolide was first discovered 
by chemical screening of the culture broth of the fungus 
F-24′707y, obtained after UV mutagenesis of the wild type 
strain, which normally produces the spirobisnaphthalene 
cladospirone bisepoxide (Bode and Zeeck 2000). However, 
the biological activity of this macrolide was not reported. 
We describe here the isolation of the active compound 
mutolide from this culture and demonstrate for the first 
time the anti-inflammatory properties of mutolide.
Results
Phylogenetic tree analysis for sample PM0651419
The fungal culture, PM0651419 was identified as Lepi-
dosphaeria nicotiae by partial sequencing of the internal 
transcribed spacer (ITS) region with ITS primers using 
polymerase chain reaction (PCR). A nucleotide-to-nucle-
otide BLAST query of the gene bank database (Altschul 
et al. 1990) recovered GQ203760.1, Lepidosphaeria nico-
tiae as the closest match to the ITS rDNA of PM0651419 
(92  %) (Fig.  1). Evolutionary analysis were performed 
using MEGA 6 (Tamura et al. 2013). The 92 % similarity 
score does not provide confident species-level identifica-
tion in the genus Lepidosphaeria, hence it was designated 
simply as a Lepidosphaeria sp.
Isolation and structural elucidation of the compound
Crude extract of fungus PM0651419 was subjected to 
vacuum liquid chromatography and organic fraction was 
generated using 100 % methanol. This organic extract was 
fractionated by HPLC which included reversed phase col-
umn (RP-C18) and water:acetonitrile (0.1 % formic acid) 
gradient as mobile phase. Fractionation of PM0651419 
gave 12 active fractions (1–4: moderate activity, 5–12: 
potent activity, retention time 0.5–6.5  min.) and only 
four fractions 5, 7, 9 and 11 were selected for analysis by 
LCMS, High-Resolution MS. The four fractions/tubes 
(5, 7, 9 and 11) were mixtures of mutolide and minor 
unidentified components. All fractions were tested for 
its effect on induced secretion of TNF-α and IL-6 and 
active fractions were further purified. Further fractiona-
tion on PM0651419-tubes 5 and 7 yielded four active 
fractions (47 J, 47 K, 47 L and 47 P). High-resolution MS 
of 47  J, 47  K and 47  P showed mutolide was present as 
a relatively pure fraction (95  %) (Additional file  1: Fig-
ures S1, S2, S3). Anti-inflammatory activity was further 
confirmed for pure compound. Isolated quantity of pure 
compound was very low and hence, large scale isolation 
was carried out for other biological studies. The isolated 
compound was characterized by spectroscopic data anal-
ysis (IR, 1H-NMR, 13CNMR, and LC–MS). As mentioned 
in Table  1, all the values were in complete accord with 
Fig. 1 Phylogenetic analysis of the ITS region sequence obtained 
from sample PM0651419 in comparison with the nearest type strain 
sequences. The tree was constructed based rRNA gene sequences 
(ITS region) using the Maximum Composite Likelihood Method
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that of the reported values (Bode et  al. 2000). Mutolide 
((3E,5S,6E,8S,9E,14R)-5,8-Dihydroxy-14-methyloxacy-
clotetradeca-3,6,9-trien-2-one) (1): soluble in methanol 
or acetone; insoluble in n-hexane or water. M.p. 168 °C—
IR (KBr): νmax 3300  cm−1 (OH), 1708 (C=O), 1641 
(C=C). 1H NMR (300 MHz, [D6] acetone) and 13C NMR 
(75.5 MHz, [D6] acetone): (Table 1). Hence the structure 
of the compound was assigned as mutolide (Fig. 2). Our 
subsequent data shows the anti-inflammatory potential 
of mutolide.
Effect of mutolide on LPS‑induced TNF‑α and IL‑6 secretion 
from THP‑1 cells
THP-1 cells are frequently used as a standard system for 
monocytes due to their similar genetic background. In 
preliminary experiment, we sought to confirm the anti-
inflammatory potential of mutolide. The anti-inflam-
matory activity was evaluated by the ability to inhibit 
LPS-induced TNF-α and IL-6 secretion. THP-1 cells 
were stimulated by LPS after addition of mutolide. After 
24  h, supernatant was collected and assayed for TNF-α 
and IL-6 levels by ELISA. Cytotoxicity was evaluated 
using MTS. Dexamethasone was used as a positive con-
trol. At 1  μM, dexamethasone inhibited the production 
of IL-6 and TNF-α from THP-1 cells by 90 % and 74 % 
respectively without significant toxicity on the cells. 
LPS stimulated THP-1 cells showed 2296 and 84  pg/ml 
of TNF-α and IL-6 secretion, respectively. As shown in 
Fig. 3a, mutolide blocked the release of TNF-α and IL-6 
by LPS-stimulated THP-1 cells in a dose-dependent 
manner with an IC50 of 1.27 ± 0.06 and 1.07 ± 0.02 µM, 
respectively, without significantly affecting viability of the 
cells. IC50 for toxicity was 32.16 ± 1.53 µM.
Effect of mutolide on LPS‑induced TNF‑α and IL‑6 secretion 
from human peripheral blood mononuclear cells
Further, we sought to evaluate the anti-inflammatory 
potential of mutolide using primary cells. For this, 
PBMCs from healthy donors were isolated and stimu-
lated with LPS after adding mutolide. After 5 h of incu-
bation, the supernatant was collected and assayed for 
measuring TNF-α and IL-6 levels by ELISA. Cytotoxicity 
Table 1 NMR data comparison for mutolide
a NMR data of mutolide reported in Bode et al. (2000)
C‑atom Reported δH (ppm)a Observed δH (ppm) Reported δc (ppm)a Observed δc (ppm)
2 – – 168.6 166.244
3 5.81 5.85 118.8 117.383
4 6.7 6.74 152.9 151.744
5 4.89 4.9 70.8 69.425
6 5.41 5.42 131.1 129.744
7 5.77 5.75 135 134.594
8 4.62 4.62 73 71.603
9 5.57 5.66 135.6 134.986
10 5.41 5.56 132.6 130.305
11 1.94 1.97 31.7 30.419
12 1.4 1.4 25 23.656
13 1.52 1.55 35.5 34.138
14 4.98 5 72.8 70.497
15 1.18 1.22 18.9 17.878
5‑OH 4.5 4.7 – –
8‑OH 3.96 4.16 – –
Fig. 2 Structure of mutolide
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of mutolide was assessed by MTS method. The positive 
control, dexamethasone at 1  µM, inhibited the secre-
tion of IL-6 and TNF-α from hPBMCs by 71  ±  3 and 
65 ± 6 %, respectively, without significant toxicity on the 
cells. Mean TNF-α and IL-6 levels observed from three 
healthy human donors in this experiment were 4055 and 
350 pg/ml, respectively. Mutolide, in this experiment mit-
igated TNF-α and IL-6 at IC50 equivalent to 1.83 ± 0.33, 
2.5 ±  0.5 µM, respectively, without affecting viability of 
hPBMCs up to 100 µM (Fig. 3b).
Effect of mutolide on anti‑hCD3/anti‑hCD28 co‑stimulated 
IL‑17 release from human peripheral blood mononuclear 
cells and its effect of proliferation of anti‑hCD3/anti‑hCD28 
co‑stimulated human peripheral blood mononuclear cells
To evaluate the effect of mutolide on another pro-inflam-
matory cytokine IL-17, anti-hCD3/anti-hCD28 co-stim-
ulated hPBMCs were used. PBMCs from healthy donors 
were isolated and stimulated with anti-hCD3/anti-
hCD28 mAb and incubated for 48 h with mutolide. After 
48  h incubation, supernatant was collected and assayed 
for IL-17 levels by homogenous time resolved fluores-
cence (HTRF) method. The anti-proliferative effect of 
mutolide on anti-hCD3/anti-hCD28 co-stimulated hPB-
MCs was measured by the incorporation of 3H thymi-
dine in these cells. Mean IL-17 level observed from three 
healthy human donors was 1906 pg/ml. Mutolide inhib-
ited IL-17 expression with an IC50 of 0.63  ±  0.04  µM. 
Whereas effect on cell proliferation was observed at IC50 
of 4.36 ± 1.02 µM (Fig. 3c) suggesting that effect on IL-17 
was selective and not due to a general cessation of pro-
liferation. Mutolide was further assessed for its effect 
on activation of the transcription factor RORγt which 
is centrally involved in IL-17 synthesis (supplementary 
information). The compound did not affect RORγt activ-
ity in a transfected cell line (Additional file 1: Figure S4) 
suggesting that mutolide may be inhibiting pathways 
ubiquitously involved in cytokine secretion.
Effect of mutolide on TNF‑α induced NF‑κB activation 
in CEM‑κB cells transfected with the κB element
It is well established that LPS as well as anti-CD3/CD28 
signal transduction leads to activation of NF-κB and 
release of cytokines such as TNF-α, IL-6 by monocytes 
and IL-17 by T cells. Accordingly to decipher the path-
way by which inhibition of induced cytokine secretion 
in THP-1 cells and hPBMCs was observed; we studied 
the effect of mutolide on NF-κB transcription using a 
CEM-κB cell line transfected with the κB binding ele-
ment. CEM-κB cells were treated with mutolide and sub-
sequently stimulated with TNF-α for a period of 16 h. We 
observed that mutolide dose dependently prevented acti-
vation of NF-κB (Fig. 4a).
Effect of mutolide on NF‑κB activation in HeLa cells
To further elucidate the effect of mutolide on the sign-
aling events involved in NF-κB activation; namely IκB 
activation followed by p65 translocation, we used TNF-α 
induced HeLa cells as a tool system. HeLa cells were 
treated with mutolide at 10 µM followed by stimulation 
with TNF-α. Mutolide inhibited phospho NF-κB trans-
location from cytoplasm to nucleus (Fig. 4b) but did not 
affect phospho IκB activation (Fig. 4c).
Effect of mutolide on p38 MAPK enzyme
Protein kinases regulate several important functions 
within cells such as metabolism, cell cycle progres-
sion, cell adhesion, etc., p38 MAPK, a serine/threonine 
Fig. 3 The effect of mutolide on a TNF‑α and IL‑6 secretion LPS‑stimulated THP‑1 cells after 24 h. Values presented are average of n = 2. Mutolide 
showed dose‑dependent inhibition of TNF‑α and IL‑6 with IC50 being 1.27 ± 0.06 and 1.07 ± 0.02 µM, respectively. CC50 for mutolide was 
32.16 ± 1.53 µM, b TNF‑α and IL‑6 secretion from LPS‑stimulated human peripheral blood mononuclear cells. Values presented are average of N = 3 
donors. Mutolide had an IC50 of 1.83 ± 0.33, 2.5 ± 0.5 and >100 µM for TNF‑α inhibition, IL‑6 inhibition and toxicity, respectively, c IL‑17 secretion 
from anti‑hCD3/anti‑hCD28 co‑stimulated hPBMCs and its effect on proliferation of anti‑hCD3/anti‑hCD28 stimulated and unstimulated hPBMCs. 
Values presented are average of N = 3 donors. Mutolide had an IC50 of 0.63 ± 0.04, 4.36 ± 1.02 µM for IL‑17 inhibition and proliferation of stimulated 
hPBMCs, respectively. All data are statistically analyzed by GraphPad Prism version 5.0. Error bars represent mean ± SEM. *p < 0.05, **p < 0.01, 
***p < 0.001
Page 5 of 10Shah et al. SpringerPlus  (2015) 4:706 
kinase, is a critical enzyme in cell proliferation and secre-
tion of cytokines. To evaluate the mechanism by which 
mutolide inhibits the secretion of LPS-induced TNF-α 
and IL-6 secretion, it was tested at 5, 25, and 50 µM for 
its effect on p38 MAPK enzyme activity. SB203580 was 
used as a positive control. At 1  µM, SB203580 showed 
90 % inhibition of p38 MAPK enzyme activity. However, 
mutolide was not active under similar experiment condi-
tions and did not inhibit p38 MAPK enzyme indicating 
that the effect of mutolide on cytokine expression and 
cell proliferation may be independent of the MAPK path-
way and may be regulated by action of mutolide on the 
NF-κB pathway (Table 2).
Effect of mutolide in vivo production of TNF‑α
To assess whether mutolide mediated inhibition of pro-
inflammatory cytokine observed in vitro could be trans-
lated into a meaningful pharmacological effect in vivo, we 
used an acute model of inflammation. Rolipram, the posi-
tive control, significantly inhibited LPS-induced TNF-α 
production. In this study, oral administration of mutolide 
at 100  mg/kg significantly inhibited LPS-induced pro-
duction of TNF-α from Balb/c mice (Fig. 5).
Fig. 4 Effect of mutolide on a TNF‑α induced NF‑κB activation in CEM‑κB cells transfected with the κB element, b translocation of phospho NF‑κB 
and c phosphorylation of IκBα. TNF‑α induced CEM‑κB cells were treated with mutolide and the effect on NF‑κB expression at the end of 16 h was 
determined. Mutolide showed inhibition of TNF‑α induce NF‑κB activation and the translocation of phospho NF‑κB, but not the phosphorylation of 
IκBα
Table 2 Percent inhibition of  p38 MAP kinase enzyme 
activity by mutolide at 5, 25, 50 µM
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Discussion
Literature implicates that there are at least 1.5 million 
fungi in nature. Several fungal metabolites are reported 
to be inhibitors of iNOS, NFκB, AP-1, JAK, STAT, 
cytokines, cyclooxygenase (COX-1 and COX-2), 3α-HSD, 
XO and PLA2 (Deshmukh and Verekar 2012). In natural 
products based drug discovery, small scale fractionation 
followed by LC–MS based de-replication has an advan-
tage of screening large number of extract libraries in 
comparatively a short span of time. The de-replication 
program along with high throughput screening in differ-
ent pharmacological indications reveals tremendous val-
uable information. Here we demonstrate for the first time 
the anti-inflammatory properties of mutolide isolated 
from the fungus Lepidosphaeria species (PM0651419). 
There are some differences between mutolide and other 
macrolides such as azithromycin, clarithomycin, etc. 
There is concern that that long-term administration of 
these macrolides can promote bacterial resistance. Non-
antimicrobial macrolides (like tacrolimus, pimecrolimus 
etc.) are in development as potential immunomodula-
tory therapies. Mutolide has been reported to have a 
weak antibacterial activity (Pettit 2011). Also, molecular 
weight of mutolide is significantly lower than other mac-
rolides. Considering this and its anti-inflammatory prop-
erties reported in this manuscript, suggests that mutolide 
if proven efficacious in a chronic model of inflamma-
tion, can be used to develop new scaffolds against spe-
cific anti-inflammatory targets using modern medicinal 
chemistry approach.
Exposure of macrophages to bacterial endotoxin or 
lipopolysaccahride is well known to activate TLR4 medi-
ated signaling cascades that initiate inflammatory gene 
expression events leading to inflammatory cytokine pro-
duction. Since, THP-1 cells are widely used cell lines to 
investigate the function and regulation of monocytes 
and macrophages (Sharif et  al. 2007) and bear resem-
blance to primary monocytes-macrophages isolated from 
healthy donors, we utilized these cells for screening and 
bioactivity guided isolation of mutolide from the fungus 
PM0651419. Our data clearly indicates that mutolide 
blocks TNF-α and IL-6 production from LPS-induced 
THP-1 cells (Fig. 3a). To further verify anti-inflammatory 
potential using primary cells, mutolide was evaluated for 
its effect on pro-inflammatory cytokine secretion from 
LPS-induced human peripheral blood mononuclear 
cells. Binding of LPS is mediated through LPS binding 
protein (LBP) and CD14 receptors expressed on the cell 
surface of cells belonging to the macrophage lineage. LPS 
induced signal transduction leads to activation of NF-κB 
and release of cytokines such as TNF-α, IL-6. Mutolide 
inhibited the secretion of TNF-α and IL-6 from LPS-
induced hPBMCs in a dose dependent manner (Fig. 3b).
To evaluate effect of mutolide on other pro-inflamma-
tory cytokines, we looked at IL-17 expression by anti-
CD3/CD28 stimulated hPBMCs. Mutolide showed dose 
dependent inhibition of IL-17 secretion (Fig. 3c) further 
corroborating its anti-inflammatory potential. RORγt 
being the transcription factor involved in the differen-
tiation of T cells into IL-17 secreting Th17 cells and cur-
rently an engaging industrial target for drug development 
(Aggarwal and Gurney 2002), we studied the effect of 
mutolide on RORγt activation. However, mutolide did 
not mitigate RORγt activation in a reporter assay (Addi-
tional file 1: Figure S1) indicating that mutolide may not 
be exerting its effect on IL-17 secretion via RORγt.
IL-17, a pro-inflammatory cytokine, is found to stimu-
late the production of many other cytokines such as IL-6, 
TNF-α, IL-1β, TFG-β, G-CSF, GM-CSF and chemokines 
such as IL-8, GRO-a, MCP-1 from many cell types. Sev-
eral studies have shown that IL-17 family is linked to 
many immune related diseases including RA, asthma, 
lupus, allograft rejection and psoriasis (Aggarwal and 
Gurney 2002; Cho et al. 2006; Ju et al. 2008).
Data from THP-1 cells and hPBMCs clearly demon-
strated that mutolide significantly inhibited LPS-induced 
TNF-α and IL-6 secretion. Similarly the compound also 
abrogated IL-17 secretion from anti-CD3/CD28 stimu-
lated hPBMCs. Cytokines secretion in most cell types is 
transcriptionally regulated by NF-κB activation. Tran-
scriptional activation of NF-κB target genes in response 
to extracellular stimuli involves translocation of NF-κB 
from cytoplasm to nucleus. In the classical pathway, 
Fig. 5 Effect of mutolide on LPS‑induced TNF‑α production in 
Balb/c mice. Mutolide was administered orally at 50 and 100 mg/kg 
followed by LPS stimulation. Values presented are average of n = 8 
mice. Mutolide significantly inhibited the LPS‑induced production of 
TNF‑α from Balb/c mice at 100 mg/kg (p < 0.05 as compared with LPS 
control). All data are statistically analyzed by GraphPad Prism version 
5.0. *p < 0.05, ***p < 0.001
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NF-κB protein is bound and inhibited by IκBα. Upon cell 
stimulation, IKK complex is activated which phosphoryl-
ates IκBα. Phosphorylation of IκBα leads to its ubiquit-
ination and proteasomal degradation and thereby NF-κB 
is released from the IκBα. Active NF-κb is further acti-
vated by phosphorylation and translocate to the nucleus. 
Inside the nucleus, NF-κB either alone or in combina-
tion with other transcription factors such as AP-1, ETS 
and STAT, they induce target gene expression. Aberrant 
activation of NF-κB is observed in several conditions, 
most notably, inflammatory tissue injury, where NF-κB 
controls the gene expression of a variety of pro-inflam-
matory mediators (Ghosh et  al. 1998; Heiss et  al. 2001; 
Tergaonkar 2006).
Many natural products that have been shown to have 
anti-inflammatory property are known to inhibit NF-κB. 
Hence, in order to decipher the signaling pathway 
through which mutolide mitigates cytokine secretion and 
given the role of NF-κB signaling in cytokine secretion, 
mutolide was tested for its effect on NF-κB. Our data 
clearly indicates that mutolide blocks TNF-α induced 
NF-κB expression in a CEM-κB cell line transfected 
with the κB element (Fig. 4a). Further, mutolide inhibits 
TNF-α induced translocation of NF-κB from cytoplasm 
into the nucleus (Fig. 4b) but has no significant effect on 
IκB activation (Fig. 4c).
In addition to NF-κB, p38 MAPK enzyme is known to 
be involved in cell proliferation and cytokine secretion 
and several p38 MAPK inhibitors are being developed for 
possible therapeutic effect on autoimmune diseases and 
inflammatory processes (Goldstein and Gabriel 2005). 
Here we showed that mutolide does not inhibit p38 
MAPK enzyme activity. This indicates that mutolide may 
exert its inhibitory effect on LPS-induced TNF-α and 
IL-6 secretion as well as anti-CD3/CD28 induced IL-17 
secretion via NF-κB inhibition. Overall our data suggests 
that mutolide shows promissory anti-inflammatory prop-
erties and this activity may be mediated through effects 
on NF-κB signaling pathway and other transcriptional 
factors activated by LPS signaling. Further detailed stud-
ies are required to elucidate mutolide’s mechanism of 
action.
Since mutolide is a small molecule which significantly 
mitigates proinflammatory cytokine secretion and dem-
onstrates inhibition of NF-κB activity, we assessed its 
potential in abrogating cytokine secretion in  vivo. Our 
data demonstrates that oral administration of mutolide 
at 50 and 100  mg/kg inhibited LPS-induced production 
of TNF-α from Balb/c mice (Fig.  5). Since plasma con-
centrations of mutolide were not evaluated it is not pos-
sible to draw a direct comparison to its in vitro effective 
concentration. However, this in  vivo study highlights 
the potential of mutolide to be effective in mitigating 
cytokine mediated systemic inflammatory conditions.
Several studies have shown that over expression of 
cytokines plays a key role in the pathogenesis of autoim-
mune disease, chronic inflammatory proliferative disease, 
bone resorption and joint diseases (Feldmann et al. 1996; 
Papp et  al. 2012; Smolen and Maini 2006). The central 
role of TNF in inflammatory disorders has been dem-
onstrated by the ability of agents that block the action of 
TNF to treat a range of inflammatory conditions, includ-
ing rheumatoid arthritis, ankylosing spondylitis, inflam-
matory bowel disease and psoriasis (Feldmann et  al. 
1996). Strategies targeting IL-6 and IL-6 signaling lead to 
effective prevention and treatment of chronic inflamma-
tory diseases (Smolen and Maini 2006). Similarly IL-17 
is a crucial cytokine expressed by Th17 cells; triggered 
by elevated IL-6. Recent data in clinical trials with anti-
bodies directed to IL-17 has shown tremendous success 
in regression of inflammatory conditions such as psori-
asis (Leonardi et al. 2012; Papp et al. 2012). Mutolide is 
a small molecule which mitigates NF-κB driven inflam-
matory cytokine secretion by both APCs as well as T 
cells. NF-κB is the master transcriptional regulator 
which mediates the secretion of TNF-α and IL-6 in the 
monocyte–macrophage lineage as well as T cell driven 
cytokines such as IL-17. Since this transcription factor is 
ubiquitous, and plays a crucial role in cell differentiation 
and regulation of specific cellular responses, mitigation 
of this regulatory factor is considered a good therapeu-
tic option for inflammation (Barnes and Karin 1997). 
The present studies have clearly indicated that mutolide 
inhibits pro-inflammatory cytokines by blocking activa-
tion of the transcription factor, NF-κB. The molecule 
when administered orally also abrogates LPS induced 
cytokine secretion in vivo. Mutolide is a small molecule 
which exerts systemic anti-inflammatory effects and can 
therefore be considered as a start-up point for developing 
new scaffolds against specific anti-inflammatory targets 
using modern medicinal chemistry approach.
Conclusions
In this study, we demonstrated the anti-inflammatory 
potential of mutolide isolated from the coprophil-
ous fungus Lepidosphaeria sp. (PM0651419). Our data 
clearly indicated that mutolide mitigates secretion of 
pro-inflammatory cytokines TNF-α, IL-6 and IL-17 
in different assays. Mechanistic evaluations indicated 
that mutolide may exert its anti-inflammatory effect via 
NF-κB inhibition. In an acute model of inflammation, 
oral administration of mutolide at 100 mg/kg showed sig-
nificant inhibition of LPS-induced release of TNF-α from 
Balb/c mice.
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Methods
Isolation and identification of fungus PM0651419
The culture PM0651419 was isolated from the horse 
dung samples collected from Rajkot, India, by the 
method described by Krug et  al. using Potato Dextrose 
Agar (PDA) medium supplemented with 50  mg/L of 
chloramphenicol (Krug 2004; Krug et al. 2004). The cul-
ture was maintained on PDA slant tubes for identifica-
tion and fermentation purpose.
Large‑scale production of the fungus
A loop full of the well grown culture from slant main-
tained on Potato dextrose agar (PDA) was transferred to a 
500 ml conical flask with 100 ml liquid medium contain-
ing soluble starch 1.5 g; soyabean meal 1.5 g; yeast extract 
0.2 g; corn steep liquor 0.1 g; glucose 0.5 g; CaCO3 0.2 g; 
NaCl 0.5  g; glycerol 1.0  g in demineralized water at pH 
5.5. This was grown on rotary shaker at 220 rpm for 72 h 
at 26 ± 1 °C and was used as seed medium. Potato dex-
trose broth medium (Hi Media) was used for production. 
The pH of the medium was adjusted to 6.5 prior to steri-
lization. Twenty-five, 1000 ml flask containing 200 ml of 
the above medium were inoculated with 1 % of the seed 
culture and incubated on rotary shaker at 220  rpm for 
72 h at 26 ± 1 °C.
Purification of compound
5 L fermentation broth was filtered through Whatman 
No. 1 filter paper to remove biomass. The filtrate was 
passed through the HP20 resin (250  ml bed volume). 
The organic compound was eluted with 1 L MeOH. The 
eluate was concentrated on rotary evaporator to remove 
methanol. The concentrated material was lyophilized to 
obtain 3.251  g of crude extract. The crude extract was 
suspended in 100 ml of water and partitioned with ethyl 
acetate. Evaporation of the ethyl acetate layer yielded a 
yellow semi solid extract (2.454  mg). Semi solid extract 
obtain from the ethyl acetate extract was subjected to 
column chromatography (SiO2, 60–120 mesh: CHCl3/
MeOH gradient 2–20 %). The fractions were tested for its 
effect on induced secretion of TNF-α and IL-6. The frac-
tions were also monitored by thin layer chromatography 
(TLC). The pure compound (590 mg) was obtained from 
fractions eluted with 1.75 % MeOH in CHCl3. The purity 
of compound was determined by HPLC and compound 
was characterized by spectroscopy.
Normal column chromatography (CC) was performed 
with distilled commercial-grade solvents. Silica gel (SiO2, 
200–300 mesh) was used for CC and GF254 (30–40 mm) 
TLCs were procured from Merck. NMR spectra: in 
acetone d-6recorded on Bruker 300  MHz spectrometer. 
ESI LC–MS: Bruker Daltonics. Flash chromatography: 
CombiFlash® Sq 16× Teledyne Technologies Company 
ISCO attached with UV/VIS detector, RediSep® Flash 
Column silica 12 g Teledyne ISCO.
Cell line and THP‑1 assay
The human monocytic cell line THP-1 (ATCC) was 
maintained in RPMI-1640 (GIBCO) supplemented with 
2  mM  l-glutamine, 100 U of penicillin per ml, 100  mg 
of streptomycin per ml with 25  mM HEPES and 10  % 
fetal bovine serum (FBS). Prior to LPS stimulation, 
25,000 cells per well were cultured for 24 h in the pres-
ence of 10  ng/ml of phorbol 12-myristate 13-acetate 
(PMA, Sigma-Aldrich). After incubation, non-adherent 
cells were removed by aspiration, and the adherent cells 
were washed with RPMI three times. Mutolide or con-
trol (0.5 % DMSO) was added to the cells and the plate 
was incubated for 30  min at 37  °C. Dexamethasone at 
1 μM was used as a positive control to assess assay valid-
ity. These cells were then stimulated with 1  µg/ml LPS 
(Sigma-Aldrich) for 24  h. The supernatants were col-
lected and stored at −80 °C until quantification of TNF-α 
and IL-6 was performed by ELISA using kits from BD 
biosciences. The cytotoxicity was evaluated by MTS assay 
(Promega) as per manufacturer’s recommendation.
Human peripheral blood mononuclear cells assay
Peripheral blood was collected from healthy human donors 
after informed consent and Independent Ethics Commit-
tee approval. Human peripheral blood mononuclear cells 
(hPBMCs) were isolated using Ficoll-hypaque density cen-
trifugation (1,077 g/ml; Sigma Aldrich) and were suspended 
in RPMI-1640 media containing 100  U/ml penicillin and 
100 µg/ml of streptomycin. For the hPBMCs assay, 1 × 106 
cells/ml were plated in a 96-well plate and mutolide was 
added at eight concentrations ranging from 100 to 0.03 µM. 
Dexamethasone at 1 μM was used as a positive control to 
assess assay validity. After 30  min, these cells were then 
stimulated with 1  µg/ml LPS for 5  h. The supernatants 
were collected and stored at −80 °C until quantification of 
TNF-α and IL-6 was performed by ELISA using kits from 
BD Biosciences. The cytotoxicity was evaluated by MTS 
assay (Promega) as manufacturer’s recommendation.
For evaluating the effect of mutolide on IL-17 release 
from hPBMCs, 96-well plates were coated with 1.5 μg/ml 
anti-human CD3 antibody and 35  ng/ml of anti-human 
CD28 antibody. For this assay, 1.25 ×  106 cells/ml were 
plated onto these coated plates and mutolide was added 
at eight concentrations ranging from 100 to 0.03  µM. 
The supernatants were collected after 48  h and stored 
at −80  °C until quantification of IL-17 was performed 
by HTRF assay using kit from Cisbio as per manufac-
turer’s instruction. In this assay, anti-proliferative effect 
of mutolide on anti-CD3/anti-CD28 co-stimulated hPB-
MCs was evaluated by thymidine uptake assay.
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NF‑κB transcription assay
The effect of mutolide on NF-κB binding was studied 
using the CEM-κB cell line. The assay was conducted as 
per published protocol (Dagia et al. 2010). The CEM-κB 
cell line was maintained in RPMI containing G418. 
Cells were stimulated with TNF-α and NF-κB activation 
was measured as a direct measure of GFP fluorescence. 
The cells were plated at a density of 50,000 cells/ml and 
treated with mutolide at various concentrations or 0.5 % 
DMSO. These cells were then stimulated with or with-
out TNF-α (1 ng/ml; R&D Systems), and the expression 
of NF-κB was observed after 16 h. The reduction of GFP 
fluorescence indicates the level of inhibition of NF-κB 
expression in the cells in the presence of mutolide. BAY 
11-7082 was used as a positive control for inhibition of 
NF-κB activation.
NF‑κB activation in HeLa cells
The specific NF-κB activity was confirmed in HeLa cells 
stimulated with TNF-α. HeLa cells were seeded at a den-
sity of 10,000 cells/well in MEM containing 0.5  % FBS 
and incubated overnight. Next day, cells were treated 
with mutolide at 10 µM. After 30 min., cells were stimu-
lated with TNF-α (25 ng/ml) for 5 min followed by fixa-
tion with 4  % para-formaldehyde for 15  min at room 
temperature. Cells were then washed with PBS and per-
meabilized using 0.5  % Triton X-100 and blocked using 
BSA. Cells were then stained with anti-phospho NF-κB 
and anti-IκBα antibodies (Cell Signaling Technology) fol-
lowed by secondary antibody and DyLight 549 contain-
ing Hoechst solution. Cells were then scanned on HCS 
platform. Data presented is an average of observations 
recorded per 1000 cells.
p38 MAPK assay
p38 kinase, ATP, mutolide and ULight-4E-BP1 peptide 
were diluted in kinase buffer. Mutolide was tested at 5, 25 
and 50 µM. SB203580 at 1 μM was used as a positive con-
trol. 2.5 µl of each p38 MAPK, mutolide, ULight-4E-BP1 
and ATP were mixed in a 384-well plate and incubated 
at room temperature for 90  min. Kinase reaction was 
stopped by adding 5 µl of 40 mM EDTA prepared in 1× 
detection buffer. Subsequently Eu-anti-phospho-eIF4E-
binding protein (2  nM) was added and plate was incu-
bated at room temperature. After 60 min, plate was read 
on Tecan microplate reader in TR-FRET mode (excita-
tion at 620 nm and emission at 665 nm).
Animals
Male Balb/c mice (8–10 weeks of age, weighing 18–20 g) 
were housed in individually ventilated cages in a tem-
perature controlled room, with access to water and 
food ad  libitum. Animal experiments were approved by 
Institutional Animal Ethics Committee of Piramal Enter-
prises Ltd., NCE Research Division.
In vivo LPS assay
Mutolide was orally administered to Balb/c mice at 50 
and 100  mg/kg in the form of a suspension in carboxy-
methyl cellulose (CMC; Sigma-Aldrich). One hour later, 
LPS dissolved in sterile pyrogen-free normal saline was 
administered i.p. The negative control group received 
normal saline as an i.p. injection; while all other groups 
received LPS. Rolipram, a PDE-4 inhibitor, has been 
shown to significantly reduce serum TNF-α level in the 
LPS-induced endotoxic shock model and was approved 
by the Institutional Animal Ethics Committee to be used 
as an a control in acute model of inflammation. Rolipram 
was administered at 30 mg/kg. After 2 h, blood was col-
lected and plasma separated by centrifugation at 2000×g 
at room temperature and stored at −80 °C until assayed 
for mouse TNF-α levels by ELISA.
Statistical analysis
Statistical analysis was performed using the software 
package GraphPad Prism. For analyzing differences 
among multiple (more than two) groups, a single fac-
tor ANOVA followed by Dunnett’s multiple comparison 
tests were used. P values <0.05 were considered statisti-
cally significant. All error bars represent standard error 
of mean.
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Additional files
Additional file 1: Figure S1. HPLC chromatograms of active frac‑
tions 47 J, 47 K, 47L, 47 P containing mutolide in pure form and parent 
PM0651419 (UV 254 nm detection).
Additional file 2: Figure S2. HRMS (Negative mode, ESI‑QTOF) of 
fraction 47 J. [M−H]− = 251.1284 m/z; [M−H+H2O]− = 269.1401 m/z. 
Fractions 47 K and 47 P showed similar HRMS profiles in −ve mode.
Additional file 3: Figure S3. HRMS (Positive mode, ESI‑QTOF) of fraction 
47 J. [M+H]+ = 253.1420 m/z; [M+Na]+ = 275.1337 m/z. Fractions 47 K 
and 47 P showed similar HRMS profiles in +ve mode.
Additional file 4: Figure S4. Effect of mutolide on RORγt activity in a 
luciferase reporter assay. Mutolide showed inhibition of RORγt reporter 
activity with IC50 of 9.5 µM. CHOK1 cells, stably transfected with RORγt‑
pFA‑CMV plasmid were seeded in a 96‑well white plate at a density of 
20,000 cells/well in MEM EBS containing 5 % FBS and incubated at 370C 
overnight. Next day, cells were transiently transfected with pFR luc plas‑
mid in Opti MEM without FBS for 5 h. After 5 h, transfection medium was 
removed and 200 µl of MEM containing 10 % FBS was added followed by 
addition of mutolide at 0.03, 0.1, 0.3, 1, 3, 10 and 30 µM. After 18‑20 h, cells 
were lysed and luciferase activity was measured and percent inhibition 
was calculated.
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